文献速递银屑病与炎症性皮肤病

窄谱中波紫外线治疗银屑病经济性高,并可显著节省外用治疗费用

Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments.
PubMed 文献 · Br J Dermatol · 2018-07-29

该研究基于英国泰赛德地区42万人口6年的治疗记录和处方数据,链接四个独立治疗中心的数据,计算窄谱中波紫外线(NB-UVB)治疗银屑病的实际成本和节省费用。结果显示每疗程平均成本257英镑,远低于英国国家卫生与临床优化研究所(NICE)的估算1882英镑;治疗后12个月内外用药物费用从128英镑降至53英镑,降幅40%,而银屑病无关处方不变。结论认为NB-UVB是低成本治疗,现有技术评估中的成本数据被高估。

要点

  • 每疗程NB-UVB平均成本257英镑(均值257±63,范围150-286),远低于NICE估算的1882英镑。
  • 治疗前12个月外用药物平均费用128英镑,占患者总药费42%;治疗后12个月降至53英镑,降幅40%。
  • 银屑病无关药物处方在治疗前后保持不变,提示节省为疾病特异性效应。

核心结论

  • NB-UVB是低成本治疗;目前卫生技术评估中使用的成本数据基于本文数据属于高估。
  • 增加或扩大NB-UVB的可及性可能通过延迟或避免许多患者使用昂贵的三线治疗而带来额外节省。

研究设计与样本

  • 对覆盖6年、人口42万的すべてNB-UVB治疗 episodes 进行综合治疗记录与处方数据的链接分析。
  • 通过汇总四个独立治疗中心的数据并使用与银屑病无关的药物处方作为阴性对照来最小化数据波动。

主要发现

  • 国民健康服务体系泰赛德地区每疗程NB-UVB平均花费257英镑(均值257±63,范围150-286,来自四个独立治疗中心),与NICE使用的估算1882英镑形成鲜明对比。
  • NB-UVB治疗前12个月,每例外用治疗平均费用为128英镑,占这些患者总药物成本的42%。
  • NB-UVB治疗后12个月,每例外用治疗费用降低40%至53英镑,而银屑病无关药物处方保持不变,提示NB-UVB的疾病特异性效应。
  • 不同工作人员运营的治疗中心之间结果高度相似,确认数据并非源于中心特异性因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Narrowband ultraviolet B (NB-UVB) treatment for psoriasis is considered expensive. However, existing data are based on estimates and do not consider indirect cost savings. OBJECTIVES: To define the actual costs of NB-UVB incurred by the service provider, as well as treatment-associated cost savings. METHODS: We performed data linkage of (i) comprehensive treatment records and (ii) prescribing data for all NB-UVB treatment episodes spanning 6 years in a population of 420 000. We minimized data fluctuation by compiling data from four independent treatment sites, and using drug prescriptions unrelated to psoriasis as a negative control. RESULTS: National Health Service Tayside spent an average of £257 per NB-UVB treatment course (mean 257 ± 63, range 150-286, across four independent treatment sites), contrasting sharply with the estimate of £1882 used by the U.K. National Institute for Health and Care Excellence. The cost of topical treatments averaged £128 per patient in the 12 months prior to NB-UVB, accounting for 42% of the overall drug costs incurred by these patients. This was reduced by 40% to £53 per patient over the 12-month period following NB-UVB treatment, while psoriasis-unrelated drug prescription remained unchanged, suggesting disease-specific effects of NB-UVB. The data were not due to site-specific factors, as confirmed by highly similar results observed between treatment sites operated by distinct staff. Finally, we detail all staff hours directly and indirectly involved in treatment, allowing direct translation of cost into other healthcare systems. CONCLUSIONS: NB-UVB is a low-cost treatment; cost figures currently used in health technology appraisals are an overestimate based on the data presented here. Creating or extending access to NB-UVB is likely to offer additional savings by delaying or avoiding costly third-line treatments for many patients.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Boswell K, Cameron H, West J, et al. Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments. Br J Dermatol. 2018. PMID: 29901862. doi:10.1111/bjd.16716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。